1. Home
  2. Labeler Index
  3. Remedyrepack Inc.
  4. 70518-1623
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Levetiracetam NDC 70518-1623 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

This is a prescription medication that contains levETIRAcetam in the form of 500mg tablets. The package contains 30 tablets. The manufacturer is Salce, located in Cranbury, NJ. The medication should be stored at a temperature of 20-25°C (58-77°F), with excursions allowed up to 15-30°C (59-86°F). The medication is repackaged by RemedyRepack Inc., located in Indiana, PA. The National Drug Code (NDC) for the product is 70518-1623-00, and the source NDC is 43547-0222-15. Expiration date and lot number are not available. Keep this medication out of the reach of children. For detailed instructions on usage, please refer to the package insert.*

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 02

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 02

This description calculates the estimated glomerular filtration rate (eGFR) using the modified Modification of Diet in Renal Disease (MDRD) equation. It takes into account the patient's age, weight, gender (if female), and serum creatinine level. The equation includes a correction factor of 0.85 for female patients. The eGFR is used to assess kidney function.*

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 03

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 03

Levetiracetam Structural Formula - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 04

Levetiracetam Structural Formula - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 04

Figure 1: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 1 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 05

Figure 1: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 1 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 05

Figure 1 shows the responder rate in Study 1, indicating the percentage of participants who experienced a reduction of more than 50% from their baseline. The graph shows that the responder rate for those taking 1000 mg/day of Levetiracetam was 45%, while those taking 3000 mg/day had a responder rate of 39.6%. In comparison, the placebo group had a responder rate of 7.4%. The results for the 3000 mg/day group were statistically significant when compared to the placebo group.*

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 06

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 06

Figure 3: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 07

Figure 3: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 07

Description: This text provides data from a study (Study 3) comparing the responder rate (>50% reduction from baseline) between two groups. The first group received a placebo (N=104) and the second group received 3000 mg/day of the drug Levetiracetam (N=180). The text shows the percentages of responders in each group, as well as a note indicating that the results for Levetiracetam were statistically significant compared to the placebo.*

Figure 4: Responder Rate (greater than or equal to 50% Reduction from Baseline) - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 08

Figure 4: Responder Rate (greater than or equal to 50% Reduction from Baseline) - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 08

figure 5 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 09

figure 5 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 09

Figure 6: Responder Rate (greater than or equal to 50% Reduction from Baseline) in PGTC Seizure Frequency per Week - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 10

Figure 6: Responder Rate (greater than or equal to 50% Reduction from Baseline) in PGTC Seizure Frequency per Week - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 10

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.